Progressive efficacy improvements with quarterly intravenous ibandronate injections: The DIVA study long term extension

被引：0
|
作者：
Czerwinski, E.
Langdahl, B.
Stepan, J.
Grant, R.
Neate, C.
Bianchi, G.
机构：
[1] Krakow Med Ctr, Dept Med, Krakow, Poland
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Charles Univ Prague, Dept Internal Med, Prague, Czech Republic
[4] Hoffmann La Roche Inc, Nutley, NJ USA
[5] Roche Prod Ltd, Pharma Dev Med Biostat, Welwyn Garden City AL7 3AY, Herts, England
[6] Osped Coletta, Div Rheumatol, Genovese, Italy
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [1] Continuing improvements in the efficacy of quarterly intravenous ibandronate injection: DIVA study long-term extension
    Lewiecki, E. M.
    Pfeilschifter, J.
    Grant, R.
    Neate, C.
    Czerwinski, E.
    BONE, 2007, 40 (06) : S301 - S301
  • [2] The diva study long-term extension: Maintained efficacy with quarterly intravenous ibandronate injection
    Bianchi, G.
    Garcia-Hernandez, P.
    Grant, R.
    Neate, C.
    Stakkestad, J. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 519 - 519
  • [3] Favourable tolerability with continued administration of quarterly intravenous ibandronate injections: The diva study long-term extension
    Reid, D. M.
    Hyldstrup, L.
    Garcia-Hernandez, P.
    Grant, R.
    Neate, C.
    Leigh, C.
    Adami, S.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S144 - S144
  • [4] Quarterly intravenous ibandronate injections provide continuing benefits in women with postmenopausal osteoporosis: DIVA study long-term extension
    Recknor, C.
    Lillestol, M.
    Grant, R.
    Neate, C.
    Recker, R. R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S453 - S453
  • [5] The DIVA study: Substantial hip bone mineral density improvements with intermittent intravenous ibandronate injections.
    Lewiecki, E.
    Adami, S.
    Bianchi, G.
    Sambrook, P.
    Hughes, C.
    Mairon, N.
    Jonkanski, I.
    Bolognese, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S70 - S70
  • [6] The mobile study long-term extension: Progressive improvements in efficacy with oral ibandronate (150mg) when administered monthly
    Reginster, J. Y.
    Cooper, C.
    Sedarati, F.
    Nea, C.
    Stakkestad, J. A.
    CALCIFIED TISSUE INTERNATIONAL, 2007, 80 : S144 - S144
  • [7] Bone resorption is effectively normalised by intermittent intravenous ibandronate injections: The DIVA study
    Reid, D. M.
    Sambrook, P. N.
    Garnero, P.
    Hughes, C.
    Masanauskaite, D.
    Stakkestad, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S70 - S71
  • [8] Favorable renal tolerability with intermittent intravenous ibandronate injections: The DIVA study.
    Civitelli, R.
    Stepan, J.
    Leigh, C.
    Ward, P.
    Burdeska, A.
    Reid, D. M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S414 - S414
  • [9] Two-year efficacy and tolerability of intermittent intravenous ibandronate injections in postmenopausal osteoporosis: the DIVA study.
    Emkey, R
    Zaidi, V
    Lewiecki, EM
    Burdeska, A
    Mairon, N
    Rowell, L
    Eisman, JA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4060 - 4060
  • [10] Efficacy and Tolerability of Intravenous Ibandronate Injections in Postmenopausal Osteoporosis: 2-Year Results from the DIVA Study
    Mikosch, P.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2008, 15 (03): : 159 - +
12345